disopyramide has been researched along with warfarin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Burroughs, AK; Haworth, E | 1 |
| Adedoyin, A; Wilkinson, GR; Zhou, HH | 1 |
| Anderson, P; Sylvén, C | 1 |
| Ishino, M; Kiriyama, A; Kiso, Y; Nishiura, T; Ogita, I; Takada, K; Yamamoto, Y | 1 |
| Johnson, JA; Livingston, TN | 1 |
| Itoh, S; Kishino, S; Miyazaki, K; Nakagawa, T; Sugawara, M | 1 |
| Hanada, K | 1 |
| Bi, C; Clarke, W; Hage, DS; Isingizwe, Z; Matsuda, R; Zhang, C | 1 |
1 review(s) available for disopyramide and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for disopyramide and warfarin
| Article | Year |
|---|---|
Differences between blacks and whites in plasma protein binding of drugs.
Topics: Adult; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Anticoagulants; Black People; Blood Proteins; Diazepam; Disopyramide; Female; Humans; Male; Orosomucoid; Protein Binding; Salicylates; Salicylic Acid; Serum Albumin; Warfarin; White People | 1997 |
17 other study(ies) available for disopyramide and warfarin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Disopyramide and warfarin interaction.
Topics: Disopyramide; Drug Interactions; Humans; Male; Middle Aged; Pyridines; Tachycardia; Warfarin | 1977 |
Differences in plasma binding of drugs between Caucasians and Chinese subjects.
Topics: Asian People; Blood Proteins; China; Diazepam; Diphenhydramine; Disopyramide; Humans; Orosomucoid; Pharmaceutical Preparations; Propranolol; Protein Binding; Salicylates; Serum Albumin; United States; Warfarin; White People | 1990 |
Evidence that disopyramide does not interact with warfarin.
Topics: Aged; Disopyramide; Drug Interactions; Humans; Middle Aged; Pyridines; Warfarin | 1983 |
Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
Topics: Animals; Binding, Competitive; Blood Proteins; Chromatography, High Pressure Liquid; Diazepam; Digitoxin; Disopyramide; HIV Protease Inhibitors; Humans; Oligopeptides; Orosomucoid; Protein Binding; Rats; Serum Albumin; Warfarin | 1996 |
Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.
Topics: Amino Acid Sequence; Disopyramide; Electrophoresis, Polyacrylamide Gel; Humans; Orosomucoid; Stereoisomerism; Warfarin | 2003 |
Lipophilicity Influences Drug Binding to α1-Acid Glycoprotein F1/S Variants But Not to the A Variant.
Topics: Disopyramide; Genetic Variation; Humans; Hydrophobic and Hydrophilic Interactions; Orosomucoid; Protein Binding; Sulfonamides; Tamsulosin; Ultrafiltration; Warfarin | 2017 |
Studies of drug interactions with alpha
Topics: Antibodies; Chlorpromazine; Chromatography, Affinity; Disopyramide; Drug Interactions; Humans; Imipramine; Orosomucoid; Pharmaceutical Preparations; Propranolol; Protein Binding; Warfarin | 2017 |